Pacific Biosciences Of California (PACB) Non-Current Debt (2010 - 2023)

Pacific Biosciences Of California has reported Non-Current Debt for 13 years, with the latest figure at $500000.0 in Q4 2023.

• On a quarterly basis, Non-Current Debt fell 78.26% year-over-year to $500000.0 in Q4 2023; TTM through Dec 2023 was $500000.0, a 78.26% decrease from a year earlier, with the FY2023 full-year figure at $500000.0, down 78.26% from the prior year.
• Non-Current Debt was $500000.0 for Q4 2023 at Pacific Biosciences Of California, down from $459.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $459.0 million in Q2 2023, with the low at $500000.0 in Q4 2023.
• Average Non-Current Debt over 4 years is $96.3 million, with a median of $3.9 million recorded in 2021.
• The sharpest annual moves came in 2019 and 2023: Non-Current Debt climbed 7.78% in 2019, then tumbled 78.26% in 2023.
• Over 4 years, Non-Current Debt stood at $15.8 million in 2019, then plunged by 75.32% to $3.9 million in 2021, then tumbled by 41.03% to $2.3 million in 2022, then sank by 78.26% to $500000.0 in 2023.
• The last three Non-Current Debt figures came in at $500000.0 (Q4 2023), $459.0 million (Q2 2023), and $2.3 million (Q4 2022), per Business Quant data.